Table 2.
Performance of VCTE, APRI, FIB-4 and NAFLD FS for the detection of significant fibrosis in HIV-monoinfected adults with elevated aminotransferases and reliable liver stiffness measurements (n=59).
| VCTE | APRI [12] | FIB-4 [19] | NAFLD FS [14] | |
|---|---|---|---|---|
| AUROC (%, 95% CI) | 93 (86–99) | 61 (46–77) | 64 (49–79) | 70 (55–85) |
| Cut-offa | ≥7.1 kPa | >1.5 | >2.67 | >0.676 |
| Sensitivity (%) | 93 | 21 | 21 | 14 |
| Specificity (%) | 73 | 82 | 89 | 96 |
| Positive predictive value (%) | 52 | 27 | 38 | 50 |
| Negative predictive value (%) | 97 | 77 | 78 | 78 |
a
Values selected from previously published cut-offs that maximize sensitivity and specificity in other liver disease populations.
Abbreviations: APRI, AST-to-platelet ratio index; AUROC, area under the receiver-operating characteristic curve; CI, confidence interval; NAFLD FS, non-alcoholic fatty liver disease fibrosis score; VCTE, vibration-controlled transient elastography.